Table 3.

Association between adherence and quality indexes.

	Rhinoconjunctivitis Total Symptom Score				Visual Analogue Scale				Combined Symptom and Medication Score
	Adha<80% (n=36), median (IQR)	Adh≥80% (n=65), median (IQR)	P valueb	Adh<80% (n=36), median (IQR)		Adh≥80% (n=65), median (IQR)	P value	Adh<80% (n=36), median (IQR)		Adh≥80% (n=65), median (IQR)	P value
Intravariation indexc	4 (3-6)	5 (4-6)	.08	5 (4-8)		7 (4-8)	.18	3 (2-3)		3 (2-4)	.32
% of zero valuesd	27 (12-72)	38 (17-55)	.66	22 (16-60)		43 (22-65)	.31	13 (0-31)		16 (4-28)	.61
Coefficient of variatione	105 (79-197)	99 (79-131)	.76	84 (60-115)		115 (76-158)	.06	77 (53-95)		74 (48-101)	.67
% of changes in trendf	25 (11-30)	34 (26-51)	<.001	23 (11-31)		33 (16-45)	.004	26 (18-30)		36 (28-51)	<.001

^aAdh: adherence.

^bMann-Whitney U test was used to compare means among the 2 groups.

^cAverage of intravariation index by subjects; for each ith subject, (1) the number of variations between 2 consecutive days has been calculated, , where t= 1,,,,,,, T is the indicator of the time point considered, y is the value of the symptom medication score considered, and I is a dummy variable, which is 1 when the condition in the brackets is verified, 0 otherwise; (2) the individual variation range has been calculated (rVAR = (max(y₁, …,y_T) – min(y1, …, y_T)) + 1/S, where S represents the unit increase for each symptom medication score, that is, S=1 for Visual Analogue Scale and Rhinoconjunctivitis Total Symptom Score and S=0.167 for Combined Symptom and Medication Score); and (3) the average of all individual intravariation index values was calculated, , for each symptom score or symptom medication score.

^d100*number of zero compiled values/actual compiled days.

^eAverage of individual coefficient of variation (100*SD/mean).

^fNumber of changes in trends (plus/minus/stable) within the differences between 2 consecutive values of symptom medication score.